INOTREM, Vandœuvre-les-Nancy, France.
UMR-S 1116, Defaillance cardiovasculaire aigue et chronique, Vandœuvre-les-Nancy, France.
Cell Mol Immunol. 2019 May;16(5):460-472. doi: 10.1038/s41423-018-0003-5. Epub 2018 Mar 22.
The triggering receptor expressed on myeloid cells-1 (TREM-1) is a receptor expressed on innate immune cells. By promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptors (TLRs), TREM-1 has been characterized as a major player in the pathophysiology of acute and chronic inflammatory diseases, such as septic shock, myocardial infarction, atherosclerosis, and inflammatory bowel diseases. However, the molecular events leading to the activation of TREM-1 in innate immune cells remain unknown. Here, we show that TREM-1 is activated by multimerization and that the levels of intracellular Ca release, reactive oxygen species, and cytokine production correlate with the degree of TREM-1 aggregation. TREM-1 activation on primary human monocytes by LPS required a two-step process consisting of upregulation followed by clustering of TREM-1 at the cell surface, in contrast to primary human neutrophils, where LPS induced a rapid cell membrane reorganization of TREM-1, which confirmed that TREM-1 is regulated differently in primary human neutrophils and monocytes. In addition, we show that the ectodomain of TREM-1 is able to homooligomerize in a concentration-dependent manner, which suggests that the clustering of TREM-1 on the membrane promotes its oligomerization. We further show that the adapter protein DAP12 stabilizes TREM-1 surface expression and multimerization. TREM-1 multimerization at the cell surface is also mediated by its endogenous ligand, a conclusion supported by the ability of the TREM-1 inhibitor LR12 to limit TREM-1 multimerization. These results provide evidence for ligand-induced, receptor-mediated dimerization of TREM-1. Collectively, our findings uncover the mechanisms necessary for TREM-1 activation in monocytes and neutrophils.
髓系细胞表达的触发受体-1(TREM-1)是一种先天免疫细胞表达的受体。TREM-1 通过促进最初由 Toll 样受体(TLRs)触发的炎症信号的放大,已被确定为急性和慢性炎症性疾病(如感染性休克、心肌梗死、动脉粥样硬化和炎症性肠病)的病理生理学中的主要参与者。然而,导致先天免疫细胞中 TREM-1 激活的分子事件尚不清楚。在这里,我们表明 TREM-1 通过多聚化而被激活,并且细胞内 Ca 释放、活性氧和细胞因子产生的水平与 TREM-1 聚集的程度相关。LPS 对原代人单核细胞中 TREM-1 的激活需要一个两步过程,包括上调,然后是 TREM-1 在细胞表面的聚集,与原代人中性粒细胞不同,LPS 诱导 TREM-1 的快速细胞膜重排,这证实了 TREM-1 在原代人中性粒细胞和单核细胞中的调节方式不同。此外,我们表明 TREM-1 的细胞外结构域能够以浓度依赖的方式同源寡聚化,这表明膜上 TREM-1 的聚集促进了其寡聚化。我们进一步表明,衔接蛋白 DAP12 稳定 TREM-1 表面表达和多聚化。TREM-1 表面的多聚化也由其内源性配体介导,这一结论得到了 TREM-1 抑制剂 LR12 限制 TREM-1 多聚化的能力的支持。这些结果为配体诱导的、受体介导的 TREM-1 二聚化提供了证据。总的来说,我们的发现揭示了单核细胞和中性粒细胞中 TREM-1 激活所需的机制。